-- Conference Call Scheduled for
5:00 p.m. ET --
SAN
DIEGO, July 28, 2022 /PRNewswire/ -- Evofem
Biosciences, Inc., (Nasdaq: EVFM) will hold a webcast and
conference call to discuss financial results and business
highlights for the second quarter ended June 30, 2022 as
follows:
|
Date:
|
Thursday, August 4,
2022
|
|
Time:
|
5:00 pm. ET (2:00pm.
PT)
|
|
Live call:
|
(800) 285-6670 (U.S.
toll-free) or
(713)
481-1320
|
|
Webcast (live and
archived) and
related slide presentation:
|
https://evofeminvestorroomcom/2022Q2Results or
https://www.webcast-eqs.com/evofem20220804/en
|
|
|
Please connect to the webcast at least 15 minutes prior to the
start of the call to download any software that may be required. If
participating by phone, please dial in approximately 15 minutes
prior to the start of the call.
About Evofem Biosciences
Evofem Biosciences, Inc.,
(Nasdaq: EVFM) is developing and commercializing innovative
products to address unmet needs in women's sexual and reproductive
health, including hormone-free, woman-controlled contraception and
protection from chlamydia and gonorrhea. The Company's first
FDA-approved product, Phexxi® (lactic acid, citric acid
and potassium bitartrate), is a hormone-free, on-demand
prescription contraceptive vaginal gel. It comes in a box of 12
pre-filled applicators and is applied 0-60 minutes before each act
of sex. The Company expects to report top-line data this fall from
its registrational Phase 3 EVOGUARD clinical trial
evaluating Phexxi for two potential new indications – prevention of
chlamydia and prevention of gonorrhea in women. Learn more at
phexxi.com and evofem.com.
Phexxi® is a registered trademark of Evofem Biosciences,
Inc.
Investor Relations Contact
Amy
Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
(917) 673-5775
View original content to download
multimedia:https://www.prnewswire.com/news-releases/evofem-biosciences-to-report-second-quarter-2022-results-and-provide-corporate-update-on-thursday-august-4-2022-301595132.html
SOURCE Evofem Biosciences, Inc.